drugset
drugset / Trial / NCT01676259

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT01676259 ↗

Phase 2 Unknown 80 enrolled Silenseed Ltd
NaSingle-groupOpen-labelTreatment

Summary

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable locally advanced pancreatic cancer combined with chemotherapy treatment. Primary Outcome: \- ORR at 6 months.

Timeline

Start
2018-03-07
Primary completion
2022-10
Completion
2023-08

Drugs

EvaluationDrugModalityDoseRoute
Subject siG12D LODER Small interfering RNA (siRNA) 2.8 mg Other
Background Gemcitabine Small molecule — —
Background Nab-paclitaxel Small molecule — —

Indications

pancreatic ductal adenocarcinoma